Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05815498 · ClinicalTrials.gov registry record · Phase 3
A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19
A Phase 3 study of COVID-19, sponsored by ModernaTX.
- Completed
- Registry status
- Phase 3
- Development phase
- 14,246
- Enrollment target
- 20
- Study locations
NCT05815498 is a Phase 3 study of COVID-19 that has completed, run by ModernaTX. The registered enrollment target is 14,246 participants, below the 55,144-participant average among 203 other COVID-19 trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT05815498, a Phase 3 study of COVID-19, has completed, sponsored by ModernaTX.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 14,246 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815 (Part 2).
Conditions Studied
Interventions
- BIOLOGICAL mRNA-1283.222
- BIOLOGICAL mRNA-1273.222
- BIOLOGICAL mRNA-1283.815
- BIOLOGICAL mRNA-1273.815
Study Locations (20)
California
- Anaheim Clinical Trials, LLC - Anaheim
- Velocity Clinical Research, Banning - Banning
- Velocity Clinical Research- Chula Vista - Chula Vista
- Benchmark Research - Colton
- Marvel Clinical Research 002, LLC - Huntington Beach
- Velocity Clinical Research Huntington Park - Huntington Park
- Velocity Clinical Research - La Mesa
- Chemidox Clinical Trials - Lancaster
- Long Beach Clinical Trials - Long Beach
- Velocity Clinical Research- Westlake - Los Angeles
Arizona
- Chandler Clinical Trials - Chandler
- Phoenix Clinical Research LLC - Phoenix
- FRC - CCT Research - Phoenix
- Headlands Research Sarasota - Scottsdale
- Clinical Research Consortium - Tempe
- Noble Clinical Research, LLC - Tucson
- Del Sol research Management LLC. - Tucson
Alabama
- Optimal Research - Huntsville
- Accel Research Sites- Achieve Clinical Research - Vestavia Hills
Arkansas
- Lynn Institute of the Ozarks - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,246 participants |
| Start Date | 2023-03-28 |
| Est. Completion | 2025-04-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05815498
The ClinicalTrials.gov registry entry for NCT05815498 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 14,246 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,144-participant average among 203 other COVID-19 trials with a reported enrollment target (74% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 4 interventions - of which mRNA-1283.222 is the first listed.
NCT05815498 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT05815498 about?
NCT05815498 is a clinical study titled "A Study of mRNA-1283 Injection Compared With mRNA-1273 Injection in Participants ≥12 Years of Age to Prevent COVID-19". The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-1283.222 versus mRNA-1273.222 (Part 1) and mRNA-1283.815 versus mRNA-1273.815 (Part 2).
What is the current status of trial NCT05815498?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 14,246 participants. The study started on 2023-03-28. Estimated completion is 2025-04-12.
What conditions does trial NCT05815498 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT05815498?
The interventions under investigation include: mRNA-1283.222 (BIOLOGICAL), mRNA-1273.222 (BIOLOGICAL), mRNA-1283.815 (BIOLOGICAL), mRNA-1273.815 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05815498?
This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05815498 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RECRUITING · Phase 3
-
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
RECRUITING · Phase 3
-
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
RECRUITING · Phase 3
-
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
RECRUITING · Phase 3
-
A Study to Learn About COVID-19 RNA-Based Variant-Adapted Vaccine Candidate(s) Against SARS-CoV-2 in Participants Ages 12 Through 64 Years Considered at Higher Risk of Severe COVID-19, and Participants Ages ≥65 Years
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Immunogenicity of NVX-CoV2705
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.